CUE
Cue Biopharma
NASDAQ: CUE · HEALTHCARE · BIOTECHNOLOGY
$14.74
+13.38% today
Updated 2026-04-30
Market cap
$57.60M
P/E ratio
—
P/S ratio
2.10x
EPS (TTM)
$-8.40
Dividend yield
—
52W range
$5 – $31
Volume
11.4M
Cue Biopharma (CUE) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-96.90%
Operating margin
8.92%
ROE
-121.10%
ROA
-44.60%
Debt/equity
0.47x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2015 | $0.00 | $-1.93M | — | — | — |
| 2016 | $0.00 | $-7.66M | — | — | — |
| 2017 | $0.00 | $-23.23M | — | — | — |
| 2018 | $1.14M | $-38.98M | -2,398.16% | -3,386.71% | -3,411.53% |
| 2019 | $3.46M | $-36.70M | 100.00% | -1,063.30% | -1,061.25% |
| 2020 | $3.15M | $-44.78M | -963.48% | -1,427.96% | -1,419.79% |
| 2021 | $14.94M | $-44.16M | 100.00% | -292.56% | -295.56% |
| 2022 | $1.25M | $-53.01M | 100.00% | -4,275.10% | -4,257.83% |
| 2023 | $5.49M | $-50.73M | -593.93% | -949.89% | -924.10% |
| 2024 | $9.29M | $-40.67M | 100.00% | -446.86% | -437.97% |
| 2025 | $27.47M | $-26.60M | 87.33% | -96.67% | -96.85% |